Exoskeleton Market Size and Share

Exoskeleton Market Analysis by Mordor Intelligence
The Global Exoskeleton Market size is estimated at USD 0.57 billion in 2025, and is expected to reach USD 1.48 billion by 2030, at a CAGR of 21.19% during the forecast period (2025-2030).
Rapid adoption is unfolding as early medical pilots convert into scaled programs, industrial ergonomics projects expand from single lines to enterprise roll-outs, and defense agencies move prototypes into limited-rate production. Artificial intelligence (AI) embedded within control software is reshaping device responsiveness, with peer-reviewed studies showing up to a 35% cut in back muscle activity during repetitive lifts, a jump that directly lowers injury claims. Parallel gains in lightweight composites, power-to-weight actuators, and battery energy density have trimmed average unit mass by roughly 30%, improving wearer comfort and session duration. The reimbursement breakthrough in the United States Medicare’s January 2024 decision to classify personal exoskeletons under the brace benefit has triggered private-payer adoption and influenced similar policy moves in Germany, South Korea, and Japan. Competitive intensity is climbing as software-centric entrants secure design wins; NVIDIA’s 2025 decision to place Ekso Bionics in its Connect program signaled that accelerated computing talent is now indispensable for sustained differentiation.
Key Report Takeaways
- By technology, the powered/active category led with 84.22% of the exoskeleton market share in 2024, while passive systems are advancing at a 22.82% CAGR through 2030.
- By mobility, mobile solutions accounted for 68.34% of the exoskeleton market size in 2024; stationary systems are projected to expand at a 24.23% CAGR between 2025-2030.
- By body part, lower-limb platforms commanded 65.45% of 2024 revenue, whereas upper-limb designs are set to grow at 27.41% CAGR to 2030.
- By component, hardware remained dominant with an 80.12% share in 2024; software is the fastest-growing element at a 29.14% CAGR to 2030.
- By geography, North America captured 40.33% of 2024 revenue, propelled by reimbursement and research spending, while Asia-Pacific is the fastest-growing region at a 23.78% CAGR to 2030.
Global Exoskeleton Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Accelerating prevalence of neuro-musculoskeletal disorders | +5.2% | Global – concentration in North America & Europe | Long term (≥ 4 years) |
Growing demand from healthcare sector | +4.8% | Global – early adoption in developed markets | Medium term (2-4 years) |
Advancement in robotic technologies | +3.5% | Global | Medium term (2-4 years) |
Favorable reimbursement frameworks | +6.1% | North America & Europe | Short term (≤ 2 years) |
AI integration in control systems | +3.5% | Global | Medium term (2-4 years) |
Lightweight materials & battery efficiency gains | +3.5% | Global | Medium term (2-4 years) |
Source: Mordor Intelligence
Accelerating Prevalence of Neuro-Musculoskeletal Disorders Requiring Advanced Assistive Rehabilitation Solutions
Spinal cord injuries affect 294,000 individuals in the United States, with 17,000 new cases added annually, creating a sizeable candidate pool for robotic gait systems, while the share of people aged ≥ 65 is projected to reach 16% of the global population by 2030, elevating demand for mobility aids.[1]Lifeward, “Annual Report 2025,” lifeward.comControlled clinical trials show that early exoskeleton intervention can lift functional recovery by up to 30% versus traditional therapy, underscoring the clinical rationale for rapid roll-out. Health-system administrators are starting to view robotic therapy as a throughput tool: units permit longer, more task-specific sessions with fewer therapists, an outcome that directly expands revenue capacity without proportionate head-count growth. Robust evidence across multiple neurological conditions stroke, multiple sclerosis, traumatic brain injury reinforces payer confidence, smoothing the path toward coverage decisions.
Growing Demand from Healthcare Sector for Robotic Rehabilitation
Hospital groups face chronic staffing gaps as rehabilitation workloads climb; surveys from 2025 show 80% of therapists reporting reduced physical strain and higher throughput when exoskeletons supplement manual assistance. Clinical benchmarking demonstrates 25-40% boosts in post-SCI walking speed after 12 weeks of structured robotic therapy at Sheltering Arms Institute, while stroke patients at BSW Rehabilitation enjoyed 32% better gait symmetry compared with conventional programs. These outcomes support a shift from pilot budgeting to multi-site procurement. Industrial engineering teams in automobile and logistics facilities are piggy-backing on medical proof points, sourcing upper-body units to curb shoulder injuries and overtime payments.
Advancement in Robotic Technologies
Georgia Tech researchers have validated a task-agnostic controller that augments hip and knee motion by 15-20% without calibration, illustrating how refined sensing and model-based control compress set-up time.[2]Georgia Institute of Technology, “Task-Agnostic AI Controller for Lower-Limb Exoskeletons,” coe.gatech.edu Combined with composite chassis elements and high-torque brushless actuators, manufacturers have shaved mean device weight by nearly one-third, pushing real-world wear time to full work shifts. Cloud dashboards on new models, such as ReWalk 7, stream motion data to clinicians who remotely tune therapy plans, closing a feedback loop previously limited to in-clinic visits. The hardware-software fusion is shaping buyer preferences: procurement teams now rank firmware over motors when scoring tenders.
Favorable Reimbursement Frameworks Emerging in Developed Healthcare Markets
Medicare’s decision to reimburse personal exoskeletons at USD 91,032 from January 2024 established a pricing anchor and persuaded a leading U.S. commercial insurer to follow suit in April 2025.[3]Centers for Medicare & Medicaid Services, “Local Coverage Article: Powered Exoskeleton Brace,” cms.govGermany’s statutory insurer BARMER mirrored the move two months earlier, bringing 8.5 million beneficiaries under coverage. Policy diffusion is evident elsewhere; South Korea’s National Health Insurance Service opened a pilot payment scheme, and Japan’s Ministry of Health launched a device-rental subsidy. Such frameworks compress buyer payback periods to fewer than four years, catalyzing order placement at Veterans Health Administration centers and regional neuro-rehab clinics.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
High capital expenditure & maintenance costs | -4.3% | Global | Medium term (2-4 years) |
Safety risks & vague guidelines | -2.7% | Global | Short term (≤ 2 years) |
Regulatory complexity across regions | -2.7% | Global | Short term (≤ 2 years) |
Limited insurance coverage in emerging markets | -4.3% | Emerging markets | Medium term (2-4 years) |
Source: Mordor Intelligence
High Capital Expenditure and Maintenance Costs Limiting Widespread Commercial Adoption
List prices range between USD 50,000-150,000, with service contracts adding USD 5,000-10,000 yearly, figures that strain smaller hospitals and mid-sized factories. The return-on-investment case hinges on preventing workplace injuries and shortening inpatient stays; however, constraints in emerging markets, where public budgets dominate spend, suppress unit volumes. Vendors are subsequently pivoting to leasing and robotics-as-a-service models that charge per usage hour, but these schemes remain nascent outside North America.
Risks Involved with Using Exoskeletons Due to Vague Safety Guidelines
A meta-analysis in Journal of NeuroEngineering and Rehabilitation flagged hazards including device misalignment and unintended motion events, prompting regulatory agencies to tighten surveillance. Fragmented classification medical device versus industrial machinery creates mixed compliance routes. The European Union’s ExosCE initiative attempts to harmonize certification by merging Medical Devices Regulation and Machinery Directive requirements, yet manufacturers targeting multi-region launches still navigate duplicative testing, extending time-to-market and pushing up cost.
Segment Analysis
By Technology: Passive Systems Gain Traction Despite Active Dominance
The powered category captured 84.22% revenue in 2024, benefitting from motor-driven assistance that supports complex gait, stair ascent, and load carriage. It forms the backbone of most rehabilitation protocols and defense prototypes. However, passive devices, such as spring-based braces that offload lower-back strain, are recording a 22.82% CAGR to 2030 as logistics firms deploy hundreds of units in distribution centers. In 2025, peer-reviewed trials confirmed passive lumbar exoskeletons could cut back-extensor activity by 35% during carton handling, bringing them into occupational health budgets. Hybrid designs are emerging: powered hip joints paired with passive spinal supports lower both energy demand and component count, pointing to a mid-term convergence of the two classes.
The cost delta remains pronounced, with passive models retailing for one-third of powered alternatives. Manufacturers leverage advanced composites and elastomeric torsion elements to maintain assistance torque while trimming weight, placing passive lines within stringent procurement caps. As sensors embed directly onto brace frames, passive units are starting to feed ergonomic analytics to enterprise dashboards, closing the data gap with their powered counterparts. These uptake catalysts position the passive cohort to absorb incremental share from budget-sensitive buyers, even as powered systems sustain utility in high-acuity therapy.

Note: Segment shares of all individual segments available upon report purchase
By Mobility: Mobile Solutions Expand Application Horizons
Mobile exoskeletons held 68.34% of 2024 global revenue, reflecting their ability to traverse varied terrain and therefore address daily-living independence, warehouse tasks, and infantry maneuvers. Battery innovations lifted operating time to 6-8 hours, 40% longer than older models, supporting full clinic shifts and continuous production cycles. Users cite psychological benefits from eye-level interaction, a factor boosting adherence in home settings. Stationary systems, although smaller today, clock a 24.23% CAGR through 2030 because they deliver high-repeatability training in constrained motor-learning phases. Medical centers position them on gantry frames where therapists fine-tune gait kinematics via augmented-reality overlays, a configuration that accelerates neuroplasticity interventions.
Interchangeable modules allow a single chassis to switch between treadmill-mounted and overground modes, blurring the mobile-stationary divide. This flexibility appeals to mid-sized rehabilitation chains seeking to amortize capital across varied patient cohorts. Vendors are consequently shipping plug-and-play add-ons, such as handrails, harnesses, and treadmill plates, that install without specialist tooling, reducing downtime.
By Body Part: Upper-Limb Applications Accelerate as Lower-Limb Maintains Dominance
Lower-limb products represented 65.45% of 2024 sales, cemented by strong clinical evidence in spinal cord injury and post-stroke gait retraining. ReWalk’s stairs-enabled model, cleared by the U.S. Food and Drug Administration in 2025, broadened functional tasks from flat walking to multilevel navigation, a leap that resonates with payers valuing home accessibility. Upper-limb lines are scaling faster, at 27.41% CAGR, thanks to exosuits reducing deltoid loading in overhead assembly and empowering stroke survivors to practice reach-and-grasp motions. Prototype elbow bracing with 93.8% torque compensation across shoulder angles is nearing commercial viability, promising fatigue relief during complex industrial cycles and fine-motor rehabilitation sessions. Full-body frames remain niche but are proven in complete paralysis trials and special-forces load-carrying pilots, setting the stage for measured growth once battery density and exoskeleton market size economics converge.
Escalating musculoskeletal claims in warehousing and construction underpin upper-body demand. Corporations calculate direct medical and replacement-worker costs, finding breakeven within two years when shoulder injury rates fall into double digits. Clinical researchers, meanwhile, leverage variable-impedance forearm actuation to encourage cortical remapping in chronic-phase stroke, amplifying cross-sector appeal.

Note: Segment shares of all individual segments available upon report purchase
By Component: Software Emerges as Growth Engine
Hardware contributed 80.12% of 2024 revenue, aligned with the capital-intensive nature of frames, motors, and sensors. Ongoing progress in carbon-fiber layups and hollow-shaft motors is lowering structure mass while boosting torque density 30% over 2020 baselines. Yet software is registering the fastest trajectory at 29.14% CAGR, as control algorithms, user interfaces, and analytics deliver tangible performance leaps. AI-driven joint-intention estimation slashes calibration time from hours to minutes, opening doors for outpatient use. Lifeward’s 2025 prototype, built with the Israeli Human-Robot Interaction Consortium, achieved autonomous decision-making that guides users away from risky motions, a feature now at the top of hospital procurement checklists.
Data platforms monetize recurring revenue: subscription dashboards aggregate session metrics, flag maintenance issues, and feed evidence files to insurers. Services training, retrofit upgrades, and remote monitoring are picking up pace as providers realize that improper fitting erodes therapeutic benefit. Ekso Bionics now bundles multi-day therapist workshops and predictive maintenance alerts, an approach mirrored by emerging vendors jockeying for share.
Geography Analysis
North America captured 40.33% of 2024 exoskeleton market revenue, supported by a mature payer ecosystem and deep venture funding. Medicare’s fixed reimbursement rate of USD 91,032 dramatically improved affordability for spinal cord injury patients, lifting device shipments to Veterans Health Administration centers and Level I trauma hospitals. U.S. industrial employers—including automotive assemblers and parcel logistics firms pilot upper-body exosuits to stem injury downtime, and these projects are progressively converting into framework agreements. Canada follows similar trajectories, with provincial workers’ compensation boards underwriting pilot programs that assess claims reduction and productivity gains.
Europe ranks second in revenue, anchored by Germany, France, and the Nordics. Germany’s BARMER coverage decision encompassed 8.5 million beneficiaries, bringing reimbursed access to nearly half of statutory-insured citizens. Research collaborations thrive under Horizon Europe grants, linking robotics labs in Aachen, Zurich, and Genoa with clinical partners. Industrial uptake is buoyed by strict ergonomic directives; automotive OEMs in Bavaria deploy shoulder-support exoskeletons on production lines to comply with musculoskeletal exposure thresholds. The evolving ExosCE certification path eases product rollout by combining medical and machinery directives into one dossier, shortening approval timelines.
Asia-Pacific is the fastest-growing cluster at 23.78% CAGR through 2030. South Korean manufacturer WIRobotics launched the WIM gait-assist robot in the United States in 2025, highlighting the region’s export ambitions mobihealthnews.com. China’s Made-in-China 2025 agenda attaches grant incentives to rehabilitation robotics factories, while Japan’s ageing demographics funnel public R&D to assistive mobility. Despite pockets of reimbursement uncertainty, industrial customers in electronics and shipbuilding sectors procure lumbar-support suits en masse to curb compensation claims. Public-private partnerships in Singapore and Australia focus on urban ageing initiatives that integrate exoskeletons with smart-home ecosystems.

Competitive Landscape
Market concentration is moderate, with the top four suppliers controlling a significant share of global revenue, yet fresh entrants nibble at specialized niches. Ekso Bionics’ USD 10 million acquisition of Parker Hannifin’s Indego line added modular lower-limb and trunk solutions, broadening the firm’s medical-industrial spectrum. ReWalk Robotics rebranded to Lifeward in 2025, underscoring a pivot from single-product manufacturer to multi-platform neuro-rehab provider. CYBERDYNE leverages long-standing Japanese pension-fund partnerships to finance the expansion of its HAL suite into elder-care facilities.
Software alliances are strategic differentiators. NVIDIA’s 2025 Connect program placement of Ekso Bionics provides access to cutting-edge AI toolchains that accelerate gait-prediction models. KULR Technology Group forged an exclusive North American distribution pact for German Bionic’s Apogee ULTRA, bundling thermal-management expertise with exosuit hardware to secure warehouse accounts. Start-ups such as HeroWear crowdsource design iterations with onsite feedback loops, while Wandercraft’s self-balancing frame clinched the 2025 SXSW Innovation Award, boosting investor confidence. White-space prospects lie in geriatrics and ageing-in-place applications, where lightweight torso cradles could defer the need for full-time caregiving.
Recent product launches emphasize connectivity: the ReWalk 7 Personal integrates cloud telemetry for personalized parameter updates, and Ekso Indego Personal’s modular battery packs extend runtime without full recharge cycles. Firms are also experimenting with pay-per-use billing; German Bionic pilots subscription pricing that aligns cost with shifts worked, a model resonating with third-party logistics firms wary of large capital outlays.
Exoskeleton Industry Leaders
-
CYBERDYNE Inc.
-
Ekso Bionics Holdings Inc.
-
Ottobock SE & Co. KGaA
-
Parker Hannifin Corporation
-
Sarcos Technology & Robotics Corporation
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- April 2025: HeroWear, a private startup specializing in occupational exosuit solutions, has successfully raised USD 5 million in Series-A funding from venture capital investor White Road Investments. The company has also partnered with Engage to enhance its collaboration with leading enterprises. The funds will be used to drive forward product development, expand HeroWear's team, and ensure the continued delivery of high-quality client service and onsite training. This strategic investment aims to support the growing install base of HeroWear’s Apex 2 exosuit, positioning the company for significant growth in the exoskeleton technology market.
- April 2025: KULR Technology Group announced a strategic partnership with German Bionic (GB) to enter the robotics market through the launch of their new business unit, KULR AI & Robotics. The collaboration will center around GB's advanced Apogee ULTRA exoskeleton technology, with KULR securing exclusive North American distribution rights. This partnership leverages GB's established customer base, which includes prominent organizations such as Dachser Intelligent Logistics, GXO, Nuremberg Airport, Canadian Tire, Currys, and Charité Hospital Berlin, positioning KULR to expand its footprint in the rapidly growing robotics and exoskeleton sectors
- April 2025: Ekso Bionics entered a non-exclusive distribution agreement with Bionic Prosthetics & Orthotics Group for the Ekso Indego Personal, marking the company's first foray into the orthotics and prosthetics industry
- March 2024: Innophys Co. Ltd commenced the sales of “Muscle Suit Soft-Power” and "Muscle Suit Every" exoskeleton systems in Slovakia and the Czech Republic in March 2024.
Global Exoskeleton Market Report Scope
As per the scope of the report, exoskeletons are the external skeletons that support and protect the body in contrast to the internal skeleton (endoskeleton). These are wearable machines that enable limb movement with amplified strength and enhance the performance of human tasks.
The exoskeleton market is segmented by treatment type, body part type, product type, and geography. By treatment type, the market is segmented into rehabilitation and augmentation. By body part type, the market is segmented into upper body and lower body. By product type, the market is segmented into stationary and mobile. The report also covers the market sizes and forecasts in major countries across different regions. For each segment, the market size is provided in terms of value (USD).
By Technology | Powered / Active | ||
Passive | |||
By Mobility | Mobile | ||
Stationary | |||
By Body Part | Upper Limb | Hand Exoskeleton | |
Arm Exoskeleton | |||
Lower Limb | Hip | ||
Knee | |||
Ankle & Foot | |||
Full Body | |||
By Component | Hardware | ||
Software | |||
Services | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East & Africa | GCC | ||
South Africa | |||
Rest of Middle East & Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Powered / Active |
Passive |
Mobile |
Stationary |
Upper Limb | Hand Exoskeleton |
Arm Exoskeleton | |
Lower Limb | Hip |
Knee | |
Ankle & Foot | |
Full Body |
Hardware |
Software |
Services |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East & Africa | GCC |
South Africa | |
Rest of Middle East & Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current value of the exoskeleton market?
The exoskeleton market reached USD 0.57 billion in 2025 and is projected to hit USD 1.48 billion by 2030.
Which region leads global revenue?
North America leads with 40.33% share, aided by Medicare reimbursement and strong R&D funding.
Which segment is growing fastest?
Software components post the steepest trajectory at a 29.14% CAGR, driven by AI-driven control and data analytics.
How do passive and powered systems differ in growth outlook?
Powered devices dominate revenue today, yet passive systems are expanding faster at 22.82% CAGR because of lower cost and simpler deployment.
What are the main barriers to adoption?
High purchase and maintenance costs, alongside safety-standard ambiguity, remain the biggest hurdles.
Are exoskeletons covered by insurance?
Yes. Medicare established a national payment rate in 2024, and several private and European insurers have since followed, accelerating uptake.